Loss of IRF-4-binding protein leads to the spontaneous development of systemic autoimmunity

被引:72
作者
Fanzo, JC
Yang, W
Jang, SY
Gupta, S
Chen, QZ
Siddiq, A
Greenberg, S
Pernis, AB
机构
[1] Columbia Univ, Dept Med, New York, NY 10032 USA
[2] Columbia Univ, Dept Pharmacol, New York, NY USA
关键词
D O I
10.1172/JCI24096
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
IFN regulatory factor 4-binding (IRF-4-binding) protein (IBP) is a novel type of activator of Rho GTPases that is recruited to the immunological synapse upon TCR stimulation. Here we demonstrate that loss of IBP leads to the spontaneous development of a systemic autoimmune disorder characterized by the accumulation of effector/memory T cells and IgG(+) B cells, profound hypergammaglobulinemia, and autoantibody production. Similar to human SLE, this syndrome primarily affects females. T cells from IBP-deficient mice are resistant to death in vitro as well as in vivo and exhibit selective defects in effector function. In the absence of IBP, T cells respond suboptimally to TCR engagement, as demonstrated by diminished ERK1/2 activation, decreased c-Fos induction, impaired immunological synapse formation, and defective actin polymerization. Transduction of IBP-deficient T cells with a WT IBP protein, but not with an IBP mutant lacking the Dbl-like domain required for Rho GTPase activation, rescues the cytoskeletal defects exhibited by these cells. Collectively, these findings indicate that IBP, a novel regulator of Rho GTPases, is required for optimal T cell effector function, lymphocyte homeostasis, and the prevention of systemic autoimmunity.
引用
收藏
页码:703 / 714
页数:12
相关论文
共 59 条
[1]   Rho signals to cell growth and apoptosis [J].
Aznar, S ;
Lacal, JC .
CANCER LETTERS, 2001, 165 (01) :1-10
[2]  
Borggrefe T, 1999, EUR J IMMUNOL, V29, P1812, DOI 10.1002/(SICI)1521-4141(199906)29:06<1812::AID-IMMU1812>3.0.CO
[3]  
2-J
[4]  
Borggrefe T, 2001, EUR J IMMUNOL, V31, P2467, DOI 10.1002/1521-4141(200108)31:8<2467::AID-IMMU2467>3.0.CO
[5]  
2-P
[6]   The immunological synapse [J].
Bromley, SK ;
Burack, WR ;
Johnson, KG ;
Somersalo, K ;
Sims, TN ;
Sumen, C ;
Davis, MM ;
Shaw, AS ;
Allen, PM ;
Dustin, ML .
ANNUAL REVIEW OF IMMUNOLOGY, 2001, 19 :375-396
[7]   Understanding Rho/Rac biology in T-cells using animal models [J].
Bustelo, XR .
BIOESSAYS, 2002, 24 (07) :602-612
[8]   Vav proteins, adaptors and cell signaling [J].
Bustelo, XR .
ONCOGENE, 2001, 20 (44) :6372-6381
[9]   GTPases and T cell activation [J].
Cantrell, DA .
IMMUNOLOGICAL REVIEWS, 2003, 192 (01) :122-130
[10]   Targeting rare populations of murine antigen-specific T lymphocytes by retroviral transduction for potential application in gene therapy for autoimmune disease [J].
Costa, GL ;
Benson, JM ;
Seroogy, CM ;
Achacoso, P ;
Fathman, CG ;
Nolan, GP .
JOURNAL OF IMMUNOLOGY, 2000, 164 (07) :3581-3590